A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects.
Angiotensin II (Ang II) type 1 (AT₁) receptor blockers (ARBs) induce multiple pharmacological beneficial effects, but not all ARBs have the same effects and the molecular mechanisms underlying their actions are not certain. In this study, irbesartan and losartan were examined because of their different molecular structures (irbesartan has a cyclopentyl group whereas losartan has a chloride group). We analyzed the binding affinity and production of inositol phosphate (IP), monocyte chemoattractant protein-1 (MCP-1) and adiponectin. Compared with losartan, irbesartan showed a significantly higher binding affinity and slower dissociation rate from the AT₁ receptor and a significantly higher degree of inverse agonism and insurmountability toward IP production. These effects of irbesartan were not seen with the AT₁-Y113A mutant receptor. On the basis of the molecular modeling of the ARBs-AT₁ receptor complex and a mutagenesis study, the phenyl group at Tyr(113) in the AT₁ receptor and the cyclopentyl group of irbesartan may form a hydrophobic interaction that is stronger than the losartan-AT₁ receptor interaction. Interestingly, irbesartan inhibited MCP-1 production more strongly than losartan. This effect was mediated by the inhibition of nuclear factor-kappa B activation that was independent of the AT₁ receptor in the human coronary endothelial cells. In addition, irbesartan, but not losartan, induced significant adiponectin production that was mediated by peroxisome proliferator-activated receptor-γ activation in 3T3-L1 adipocytes, and this effect was not mediated by the AT₁ receptor. In conclusion, irbesartan induced greater beneficial effects than losartan due to small differences between their molecular structures, and these differential effects were both dependent on and independent of the AT₁ receptor.
Fujino
Masahiro
M
Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
Miura
Shin-ichiro
S
Kiya
Yoshihiro
Y
Tominaga
Yukio
Y
Matsuo
Yoshino
Y
Karnik
Sadashiva S
SS
Saku
Keijiro
K
D041721:3T3-L1 Cells; D052242:Adiponectin / Q000378:metabolism; D047228:Angiotensin II Type 1 Receptor Blockers / Q000737:chemistry* / Q000494:pharmacology*; D000818:Animals; D001713:Biphenyl Compounds / Q000737:chemistry / Q000494:pharmacology; D019556:COS Cells; D002460:Cell Line; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000378:metabolism; D002522:Chlorocebus aethiops; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D057809:HEK293 Cells; D006801:Humans; D000077405:Irbesartan; D007668:Kidney / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D019808:Losartan / Q000737:chemistry / Q000494:pharmacology; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism; D047495:PPAR gamma / Q000378:metabolism; D044140:Receptor, Angiotensin, Type 1 / Q000187:drug effects* / Q000502:physiology*; D013777:Tetrazoles / Q000737:chemistry / Q000494:pharmacology
D052242:Adiponectin; D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D018932:Chemokine CCL2; D016328:NF-kappa B; D047495:PPAR gamma; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D000077405:Irbesartan; D019808:Losartan